Immune Checkpoint Blockade in Cancer Therapy
- PMID: 25605845
- PMCID: PMC4980573
- DOI: 10.1200/JCO.2014.59.4358
Immune Checkpoint Blockade in Cancer Therapy
Abstract
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
© 2015 by American Society of Clinical Oncology.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest are found in the article online at
Figures
![Fig 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4980573/bin/zlj9991050350001.gif)
![Fig 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4980573/bin/zlj9991050350002.gif)
Similar articles
-
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22. Eur J Cancer. 2017. PMID: 28648699
-
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.J Chin Med Assoc. 2017 Jan;80(1):7-14. doi: 10.1016/j.jcma.2016.08.005. Epub 2016 Sep 29. J Chin Med Assoc. 2017. PMID: 27693088 Review.
-
Managing immune checkpoint-blocking antibody side effects.Am Soc Clin Oncol Educ Book. 2015:76-83. doi: 10.14694/EdBook_AM.2015.35.76. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993145 Review.
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 Jan 23. Curr Opin Immunol. 2015. PMID: 25621841 Review.
Cited by
-
Trends in the surgical treatment for metastatic spinal tumor in Japanese administrative data between 2012 and 2020.Int J Clin Oncol. 2024 Jul;29(7):911-920. doi: 10.1007/s10147-024-02537-9. Epub 2024 Jun 3. Int J Clin Oncol. 2024. PMID: 38829471
-
NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.Cancer Biol Ther. 2024 Dec 31;25(1):2358551. doi: 10.1080/15384047.2024.2358551. Epub 2024 May 30. Cancer Biol Ther. 2024. PMID: 38813753 Free PMC article.
-
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment.Int J Nanomedicine. 2024 May 21;19:4533-4568. doi: 10.2147/IJN.S455213. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38799699 Free PMC article. Review.
-
Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study.Cancers (Basel). 2024 May 16;16(10):1892. doi: 10.3390/cancers16101892. Cancers (Basel). 2024. PMID: 38791970 Free PMC article.
-
Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors.Cancers (Basel). 2024 May 9;16(10):1811. doi: 10.3390/cancers16101811. Cancers (Basel). 2024. PMID: 38791890 Free PMC article.
References
-
- Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972–1975. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials